Fusion Antibodies Seals £250k IP Deal, Supporting Finn Therapeutics’ Fundraising

Fusion Antibodies signs £250,000 IP transfer with Finn Therapeutics – here’s what the RNS really says

Fusion Antibodies (AIM: FAB) has agreed to transfer ownership of certain background intellectual property to an existing client, Finn Therapeutics Ltd. The IP covers a novel rabbit antibody, with related reach-through to the humanised sequences. In plain English, Fusion is selling underlying rights to an antibody they worked on, with associated rights tied to the humanised versions.

The headline number is a one-off £250,000 payment to Fusion. Crucially, the company says the entire fee will be recognised in the current financial year ending 31 March 2026. Given this RNS dropped on 30 March, that is a timely boost to the reported revenue line.

What exactly has been sold, and why now?

Fusion is a Belfast-based contract research organisation focused on pre-clinical antibody discovery and engineering. Its bread and butter is doing the specialist lab work that helps biotechs and pharma get antibody drugs ready for the clinic. In this deal, Fusion is transferring background IP for a novel rabbit antibody to Finn Therapeutics, an existing client that has been placing a series of projects with the company.

The agreement includes reach-through to the humanised sequences. Reach-through typically refers to rights connected to downstream outputs that originate from the IP. The RNS does not disclose specific commercial terms beyond the headline £250,000 and the inclusion of reach-through, nor any future milestones or royalties.

Why now? The RNS is candid about market conditions. Fusion notes small biotech companies are facing challenging investment conditions and says the move is designed to support Finn’s fundraising. The company has agreed tailored payment terms to allow those fundraising activities to proceed. Put simply, Fusion is being flexible to help the client secure capital and progress the programme.

Key facts from the RNS

Why this matters for Fusion investors

First, the timing. Recognising the full £250,000 before year-end provides a clear, near-term uplift to reported revenue. For a services-led business like Fusion, that helps tidy up the close of FY26 and may soften any variability elsewhere in the order book.

Second, relationship value. The RNS emphasises Finn has been placing a series of projects and intends to keep doing so as the programme advances. That points to potential follow-on work for Fusion in discovery, engineering or analytics as the asset moves through humanisation and beyond. CEO Adrian Kinkaid frames this as part of Fusion’s strategy to be the collaborative research partner of choice for antibody therapeutics.

Third, commercial trade-offs. By transferring background IP and related reach-through, Fusion is monetising now. The potential downside is reduced long-term optionality on this asset. The RNS does not mention any future milestones or royalties, so investors should treat this as a clean, one-off monetisation unless told otherwise.

The client angle – fundraising de-risked

Finn’s CEO calls the deal a significant de-risking event that streamlines fundraising and accelerates clinical entry for a first-in-class oncology candidate. That language matters. Investors often want clean ownership when backing asset-centric biotechs, and background IP wrinkles can be a sticking point in diligence. Transferring ownership helps remove friction for Finn, which in turn should keep the programme moving and drive demand for Fusion’s ongoing services.

Fusion also highlights the broader market reality: it is tough out there for small biotech. Creative deal structures that balance near-term cash for Fusion with client-friendly terms are pragmatic. The tailored payment schedule suggests cash receipts may be staged, though the revenue is recognised this year – something to keep an eye on.

Positives and watch-outs

• Positive – Revenue boost on the line: The entire £250,000 hits FY26 revenue, arriving just before year-end.
• Positive – Client stickiness: Finn intends to continue placing work as the programme advances, supporting utilisation and pipeline.
• Positive – Commercial agility: Tailored terms show Fusion can craft solutions that help clients raise capital and keep programmes alive.
• Watch-out – One-off in nature: This is not recurring revenue, and the RNS does not outline any back-end economics such as milestones or royalties.
• Watch-out – Cash timing: Payment terms are tailored and not disclosed, so cash collection may be phased. Monitor subsequent updates.
• Watch-out – Future upside traded for certainty: Transferring reach-through alongside IP may cap long-term upside from this specific asset.

What could move the story next

• Confirmation of cash receipts under the tailored payment terms.
• Further project awards from Finn as the humanised antibody progresses.
• Any disclosure on additional economics tied to the transferred IP (not currently disclosed).
• Broader order intake trends as Fusion continues to market its humanisation expertise, including its CDRx platform.

My take – a tidy year-end boost with strategic relationship value

This looks like a sensible, relationship-first deal. It gives Fusion a neat year-end revenue bump of £250,000, supports a client through a choppy funding market, and keeps the door open for more services work as the asset advances. The flip side is that it is a one-off, and the inclusion of reach-through in the transfer suggests reduced long-term optionality on this asset specifically.

Net-net, I’d mark it as modestly positive. It reinforces Fusion’s positioning as a collaborative CRO, shows commercial pragmatism, and strengthens a client tie-in that could translate into further projects. Keep an eye on cash timing and any subsequent updates on Finn’s fundraising and programme milestones. If those fall into place, this small transaction could have outsized relationship and pipeline benefits for Fusion.